Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

   Frailty score
0 1 2 3 4
Total participants: N = 581 N = 581 N = 173 N = 195 N = 109 N = 88 N = 16
Age, years: N (%)
 Mean [range] 53.4 [22–81] 54.3 [29–72] 54.3 [22–76] 51.7 [26–75] 51.3 [26–81] 55.75 [35–81]
 < 50 205 (35.3) 57 (32.9) 58 (29.7) 46 (42.2) 39 (44.3) 5 (31.3)
 50–64 284 (48.9) 87 (50.3) 101 (51.8) 49 (45.0) 39 (44.3) 8 (50.0)
 ≥ 65 92 (15.8) 29 (16.8) 36 (18.5) 14 (12.8) 10 (11.4) 3 (18.7)
Race: N (%)
 White 518 (89.2) 158 (91.3) 178 (91.3) 94 (86.2) 73 (83.0) 15 (93.8)
 Non-white 63 (10.8) 15 (8.7) 17 (8.7) 15 (13.8) 15 (17.0) 1 (6.2)
Education: N (%)
 High school or below 142 (24.4) 37 (21.4) 42 (21.5) 30 (27.5) 27 (30.7) 6 (37.5)
 Some college or above 439 (75.6) 136 (78.6) 153 (78.5) 79 (72.5) 61 (69.3) 10 (62.5)
Marital status: N (%)
 Married/long-term relationship 422 (72.6) 139 (80.3) 139 (71.3) 71 (65.1) 66 (75.0) 7 (43.8)
 Others 159 (27.4) 34 (19.7) 56 (28.7) 38 (34.9) 22 (25.0) 9 (56.2)
Cancer stage: N (%)
 I 158 (27.2) 50 (28.9) 59 (30.3) 27 (24.8) 18 (20.4) 4 (25.0)
 II 286 (49.2) 94 (54.3) 85 (43.6) 56 (51.4) 44 (50.0) 7 (43.8)
 III 108 (18.6) 24 (13.9) 42 (21.5) 20 (18.3) 18 (20.5) 4 (25.0)
 Unknown 29 (5.0) 5 (2.9) 9 (4.6) 6 (5.5) 8 (9.1) 1 (6.2)
Type of treatment: N (%)
 Adjuvant 481 (82.8) 145 (83.8) 154 (79.0) 92 (84.4) 76 (86.4) 14 (87.5)
 Neoadjuvant 100 (17.2) 28 (16.2) 41 (21.0) 17 (15.6) 12 (13.6) 2 (12.5)
Type of chemotherapy: N (%)
 Anthracycline 278 (47.9) 85 (49.1) 91 (46.7) 57 (52.2) 38 (43.2) 7 (43.8)
 Non-anthracycline 303 (52.1) 88 (50.9) 104 (53.3) 52 (47.8) 50 (56.8) 9 (56.2)
Growth factor: N (%)
 Yes 471 (81.1) 147 (85.0) 152 (77.9) 89 (81.7) 70 (79.5) 13 (81.3)
 No 110 (18.9) 26 (15.0) 43 (22.1) 20 (18.3) 18 (20.5) 3 (18.7)